期刊文献+

Epidemiology of ADRs in Internal Medicine, HCC

Epidemiology of ADRs in Internal Medicine, HCC
下载PDF
导出
摘要 We aimed to characterize, and analyze the presence of factors such as polypharmacy and personal medical history that predispose to Adverse Drug Reactions (ADRs) and potential preventability of these. The Civil Hospital of Culiacan (HCC), in Sinaloa, where the study was conducted has 80 beds in total, in which the Department of Internal Medicine with 24 beds: 12 lbr men and 12 for women, we found the part of the share to contribute to the 200,000 cases of ADRs that according with the WHO each of the countries members report ever), year to the Uppsala Monitoring Centre. We have not only but also ordered frequency of drugs, pathologies, and analytical tests of the hospitalized patients.
机构地区 Faculty of Medicine
出处 《Journal of Life Sciences》 2016年第1期54-57,共4页 生命科学(英文版)
关键词 ADRS hospitalized patients POLYPHARMACY PHARMACOVIGILANCE analytical tests. 药物不良反应 流行病学 内科 肝癌 监测中心 住院病人 ADR 预防性
  • 相关文献

参考文献14

  • 1Laurence. D.. and Carpenter, J. 1998. “A Dictionary of Pharmacology and Allied Topics.” 2nd ed. Amsterdam: Elsevier: 8-9.
  • 2Stephens. M. D. B. 1998. Definitions and Classifications of Adverse Reaction Terms.” In: Stephens, M. D. B., Talbot J. C. C., Routledge. P. A., Eds. The detection of new adverse reactions. 4th ed. London: Macmillan Reference: 32-44.
  • 3Farhan, A. K., Sheikh, N., Najmul H., and Hitesh. M.2013. “A Prospective Study on Prevalence of Adverse Drug Reactions due to Antibiotics Usage in Otolaryngology Department of a Tertiary Care Hospital in North India.” International Journal of Basic & Clinical Pharmacology 2 (5): 548.
  • 4Karch, F. E. 1975. “Lasagnal. Adverse Drug Reactions. ACritical Review.” JAMA 234: 1236-41.
  • 5Hazell, L., and Shakir, S. A. W. 2006. “Under-reporting of Adverse Drug Reactions: a Systematic Review.” Drug Saf 29 (5): 385-96.
  • 6European Commission. Proposal for a regulation amending, as regards pharmacovigilance of medicinal products for human use. Regulation (EC) No 726/2004. Impact assessment. 2008. Available at: http://ec.europa. eu/health/files/pharmacos/pharmpack_12_2008/pharmaco vigilance-ia-voll_en.pdf. Accessed 3 Sept 2014. (as cited in Jacoline C. Bouvy, et al., (2015) 38: 437-53).
  • 7Leavy, P. M. 1991. “Adverse Reaction in Children. Special Considerations in Prevention and Management.” Drug Safety 6: 171-82.
  • 8Jacoline, C. B., Marie, L. De B., and Marc, A. K. 2015. “Epidemiology of Adverse Drug Reactions in Europe: A Review of Recent Observational Studies.” Drug Saf 38: 437-53 DOI 10.1007/s40264-015-0281 -0.
  • 9Merida, F. 2013. “Carolina. Reacciones Adversas aAntibioticos Betalactamicos en el Area Este de Murcia.” Departamento de Ciencias Sociosanitarias 1: 34.
  • 10Noelia, S., Liriana, L., Hector, T., Adriana, S., Gustavo,G., and Luciana, N. 2008. “Reacciones Adversas a Medicamentos en nifios Hospitalizados: un Problema de salud publica.” Rev. Med. Urug. 24: 161-6.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部